A Phase 2 open label, study to determine the safety, efficacy and pharmacokinetic profile of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne Muscular Dystrophy.
Phase of Trial: Phase II
Latest Information Update: 10 Sep 2018
At a glance
- Drugs ATL 1102 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Antisense Therapeutics
- 06 Sep 2018 Status changed from not yet recruiting to recruiting.
- 09 Jun 2018 Status changed from planning to not yet recruiting.
- 30 May 2018 New trial record